|
Antiinflammatory activity against D-adjuvant arthritis in injected rat paw at the dose of 25 mg/kg by oral administration
|
Rattus norvegicus
|
86.0
%
|
|
|
Antiinflammatory activity against D-adjuvant arthritis in uninjected rat paw at the dose of 25 mg/kg by oral administration
|
Rattus norvegicus
|
100.0
%
|
|
|
Antiinflammatory activity dosed orally against carrageenan induced rat paw edema(CPE)
|
Rattus norvegicus
|
18.0
%
|
|
|
Antitumor activity against S180 cells implanted in mouse at 30 mg/kg, ip
|
Mus musculus
|
72.94
%
|
|
|
Antitumor activity against H22 cells implanted in mouse at 30 mg/kg, ip
|
Mus musculus
|
72.02
%
|
|
|
Antitumor activity in H22 cells xenografted ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv after 4 days
|
Mus musculus
|
56.3
%
|
|
|
Antitumor activity in mouse xenografted with S180 cells assessed as inhibition of tumor growth at 30 mg/kg/day, ip after 10 days
|
Mus musculus
|
63.5
%
|
|
|
Antitumor activity in mouse xenografted with H22 cells assessed as inhibition of tumor growth at 30 mg/kg/day, ip after 10 days
|
Mus musculus
|
36.2
%
|
|
|
Antitumor activity in mouse H22 cell xenografted mouse at 20 mg/kg/day, iv after 4 days
|
Mus musculus
|
54.3
%
|
|
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy
|
Homo sapiens
|
4.7
%
|
|
|
Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as inhibition of tumor weight at 100 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days relative to control
|
Mus musculus
|
74.5
%
|
|
|
Anticancer activity against mouse S180 cells xenografted in ICR mouse assessed as tumor weight inhibition at 100 mg/kg, ip relative to control
|
Mus musculus
|
91.68
%
|
|
|
Antitumor activity against mouse S180 cells xenografted in Kunming mouse assessed as tumor growth inhibition rate at 20 mg/kg, po administered for 10 days relative to control
|
Mus musculus
|
81.72
%
|
|
|
Antitumor activity against mouse H22 cells xenografted in Kunming mouse assessed as tumor growth inhibition rate at 20 mg/kg, po administered for 10 days relative to control
|
Mus musculus
|
56.24
%
|
|
|
Antitumor activity against mouse H22 tumor-nearing ICR mouse assessed as inhibition of tumor growth at 10 mg/kg, ip for 7 days measured on day 9
|
Mus musculus
|
41.74
%
|
|
|
Antitumor activity against mouse H22 cells xenografted in kunming mouse assessed as inhibition of tumor growth at 15 mg/kg, ip for 7 days
|
Mus musculus
|
55.0
%
|
|
|
Antitumor activity against human H22 cells xenografted in Kunming mouse assessed as reduction in tumor volume at 20 mg/kg, po qd for 10 days
|
Homo sapiens
|
72.0
%
|
|
|
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by MTT assay
|
Homo sapiens
|
90.0
nM
|
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay
|
Homo sapiens
|
240.0
nM
|
|
|
Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay
|
Homo sapiens
|
150.0
nM
|
|
|
Antiproliferative activity against Homo sapiens (human) K562 cells after 48 hr by MTT assay
|
Homo sapiens
|
153.0
nM
|
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by trypan blue assay
|
Homo sapiens
|
160.0
nM
|
|
|
Antitumor activity against mouse LLC cells xenografted in mouse assessed as tumor inhibition at 30 mg/kg, ip qd for 7 days measured every 3 days for 21 days
|
Mus musculus
|
85.6
%
|
|
|
Antitumor activity against mouse Sarcoma 180 cells xenografted in mouse assessed as tumor inhibition at 30 mg/kg, ip qd for 7 days measured every 3 days for 21 days
|
Mus musculus
|
88.7
%
|
|
|
Antitumor activity against human H22 cells transplanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post tumor transplantation
|
Homo sapiens
|
53.7
%
|
|
|
Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post inoculation measured at day 25 of tumor transplantation
|
Homo sapiens
|
53.7
%
|
|
|
Antitumor activity against mouse S180 cells implanted in mouse assessed as inhibition of tumor growth at 40 mg/kg
|
Mus musculus
|
54.8
%
|
|
|
In vivo antitumor activity against human H22 cells xenografted in mouse assessed as tumor growth inhibitory ratio at 30 mg/kg, ip administered after 7 days of tumor transplantation measured at 25th day after tumor inoculation
|
Homo sapiens
|
53.7
%
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)
|
Staphylococcus aureus subsp. aureus
|
2.64
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)
|
Escherichia coli
|
1.99
%
|
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
1.43
%
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
7.22
%
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
15.65
%
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
4.42
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600
|
Acinetobacter baumannii
|
0.33
%
|
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
-2.64
%
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
0.13
%
|
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-8.46
%
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
1.2
%
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Staphylococcus aureus subsp. aureus
|
22.17
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Acinetobacter baumannii
|
-9.14
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)
|
Escherichia coli
|
1.21
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
-5.32
%
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
24.47
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.2
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.2
%
|
|
